查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017206

口服疫苗市場：按疫苗類型、適應症、年齡層和分銷管道分類－全球市場預測（2026-2032 年）

Oral Vaccine Market by Vaccine Type, Disease Indication, Age Group, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，口服疫苗市值將達到 41.6 億美元，到 2026 年將成長至 44.8 億美元，到 2032 年將達到 73.4 億美元，複合年成長率為 8.43%。

主要市場統計數據
基準年（2025 年） 41.6億美元
預計年份（2026年） 44.8億美元
預測年份（2032年） 73.4億美元
複合年成長率 (%) 8.43%

本文全面說明了口服疫苗的創新、其公共衛生重要性、科學進展及其在全球範圍內的策略和商業性意義。

在不斷發展的預防醫學領域，口服疫苗正逐漸成為至關重要的治療方法，在給藥、分發和患者接受度方面具有顯著優勢。過去十年，藥物科學、黏膜免疫學和遞送技術的進步重新激發了研發人員和公共衛生機構的關注。這些創新旨在降低注射疫苗的接種門檻，提高熱穩定性以減輕低溫運輸負擔，並利用黏膜免疫反應更有效地抑制病原體傳播。

對科學、監管、分銷和患者主導的變革性變化進行分析，這些變化正在重新定義口服疫苗開發和供應的範式。

疫苗領域正經歷著一場變革性的轉變，其驅動力包括技術突破、相關人員期望的轉變以及法規結構的不斷改進。在科學層面，mRNA平台、載體設計和抗原穩定性的進步，使得過去無法實現的口服給藥方式成為可能。同時，藥物科學的進步也為這些進展提供了補充，這些進展能夠保護不穩定的分子免受胃腸道分解，並靶向誘導粘膜免疫。因此，研發重點日益集中在維持黏膜免疫、降低劑量策略、簡化給藥途徑。

評估美國在 2025 年實施的關稅措施對供應鏈策略、採購趨勢以及製造業在地化相關考量的影響。

美國2025年實施的關稅政策調整的累積影響，為疫苗研發、生產和採購機構帶來了新的考量。這些貿易措施旨在實現更廣泛的產業戰略目標，並影響疫苗價值鏈中的多個環節，包括活性成分、輔料、專用包裝材料以及填充和表面處理工程工藝設備的採購。因此，擁有全球分散式供應鏈的企業需要重新評估籌資策略和成本結構，以降低進口關稅增加和港口手續延誤帶來的風險。

關鍵的細分見解，整合疫苗平台類型、目標疾病、人口統計需求和分銷管道，為確定開發和商業化方案提供有價值的資訊。

要了解市場，需要有系統地掌握產品、臨床、人口統計和分銷等方面的知識，因為這些方面都會影響研發重點和商業性策略。根據疫苗類型，市場分析涵蓋結合疫苗、去活化疫苗、減毒活病毒疫苗、mRNA疫苗和次單位疫苗。考慮到每種疫苗平台在口服給藥方面都存在獨特的製劑挑戰和免疫學特性，這些差異會影響抗原穩定性、給藥方案以及保護性輔料和遞送介質的選擇等決策。

區域洞察：美洲、歐洲、中東和非洲以及亞太地區的差異如何推動監管、製造和分銷策略的差異化。

區域趨勢對疫苗研發重點、監管合作和分銷模式產生顯著影響，因此需要在全球市場採取差異化策略。在美洲，官民合作關係、先進的臨床試驗基礎設施和成熟的商業生態系統通常能夠明確新給藥技術的核准流程，而區域生產能力和採購框架則會影響本地化和策略合作方面的決策。此外，不同國家免疫規劃和私部門通路的支付方結構和專案重點也會影響市場滲透率。

本報告從公司層級提供了策略見解，闡述了成熟的製造商、生物技術創新者、CDMO 和相關技術公司如何塑造口服疫苗領域的競爭格局。

口服疫苗領域的競爭動態呈現出多元化的態勢，既有成熟的疫苗生產商，也有專注於生物技術創新的企業、合約研發生產機構（CDMO）以及製劑技術供應商。成熟的生產商在規模化生產、法規遵循和大規模分銷方面擁有豐富的經驗，一旦技術難題得到解決，便能迅速將後期候選產品推向市場。生技公司和大學衍生企業提供顛覆性的平台技術和早期科學研究成果，特別是在黏膜免疫學、口服mRNA遞送和保護性賦形劑系統等領域。

為領導者提供切實可行的建議，以透過技術投資、監管合作、供應鏈多元化和有針對性的商業化來加速口服疫苗的研發。

產業領導者應採取積極主動、多管齊下的策略，將科學潛力轉化為易於取得的口服疫苗解決方案，同時管控商業性和地緣政治風險。首先，他們必須投資於平台能力建設，以解決製劑穩定性和黏膜免疫抗原性，並透過與製劑專家和學術機構合作，加速臨床前知識的獲取，降低臨床應用風險。同時，他們應儘早整合監管策略，與監管機構合作，明確新型給藥途徑的證據要求，從而縮短研發週期，並降低不不確定性。

透明的調查方法結合了與專家的直接訪談、文獻整合、案例研究分析和資料檢驗，確保了研究結果的平衡性和可操作性。

本研究採用嚴謹的調查方法，結合一手和二手調查資料，透過綜合分析得出可靠且令人信服的結論。一手調查包括對疫苗研發、臨床研究、監管事務、生產營運和公共衛生採購等領域的專家進行結構化訪談和諮詢，從而深入了解技術挑戰和策略重點。此外，本研究也分析了相關的同儕審查文獻、臨床試驗註冊資訊、監管指南和技術白皮書，使研究結果與當代科學和政策緊密結合。

總結部分重點闡述了口服疫苗的潛力、仍然存在的科學和操作方面的挑戰，以及產業和政策制定者需要採取協調行動。

總之，口服疫苗為擴大疾病預防手段提供了策略機遇，其優勢在於無需注射、可能增強黏膜免疫力，且分發效率高，符合現代公共衛生優先事項。科學技術的進步正逐步消除抗原穩定性和胃腸道遞送方面的傳統障礙，監管流程也在積極參與下得到簡化。然而，挑戰依然存在，包括需要獲得涵蓋所有年齡層的可靠安全性和有效性數據、可擴展的生產流程以及能夠適應基礎設施容量波動的靈活供應模式。

目錄

第1章 引言

第2章 分析方法

  • 分析設計
  • 分析框架
  • 市場規模預測
  • 數據三角測量
  • 分析結果
  • 分析的前提條件
  • 分析的局限性

第3章執行摘要

  • 首席體驗長的觀點
  • 市場規模和成長趨勢
  • 市佔率分析（2025 年）
  • FPNV定位矩陣（2025）
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入（GTM）策略

第5章 市場洞察

  • 消費者分析與最終用戶觀點
  • 消費者體驗基準測試
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第6章：美國關稅的累積影響（2025 年）

第7章：人工智慧（AI）的累積影響（2025 年）

第8章 口服疫苗市場：依疫苗類型分類

  • 結合疫苗
  • 去活化疫苗
  • 減毒活病毒疫苗
  • 藥效疫苗
  • 次單位疫苗

第9章 口服疫苗市場：依適應症分類

  • 流感
  • 諾羅病毒
  • 脊髓灰質炎
  • 輪狀病毒

第10章 口服疫苗市場：依年齡層別分類

  • 成人
  • 老年人
  • 兒童

第11章 口服疫苗市場：依通路分類

  • 醫院和診所
  • 網路藥房
  • 藥局

第12章 口服疫苗市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 口服疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 口服疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國口服疫苗市場

第16章：中國口服疫苗市場

第17章 競爭格局

  • 市場集中度分析（2025 年）
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析（2025 年）
  • 產品系列分析（2025 年）
  • 基準分析（2025 年）
  • AstraZeneca plc
  • Bharat Biotech International Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Moderna, Inc
  • Panacea Biotec Ltd.
  • PT Bio Farma（Persero）
  • Sanofi SA
  • Sinovac Biotech Ltd
  • Valneva SE
Product Code: MRR-035DA3C63714

The Oral Vaccine Market was valued at USD 4.16 billion in 2025 and is projected to grow to USD 4.48 billion in 2026, with a CAGR of 8.43%, reaching USD 7.34 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.16 billion
Estimated Year [2026] USD 4.48 billion
Forecast Year [2032] USD 7.34 billion
CAGR (%) 8.43%

Comprehensive introduction framing oral vaccine innovation, public health relevance, scientific advancements, and strategic commercial implications worldwide

Oral vaccines are emerging as a pivotal modality in the evolving landscape of preventive medicine, offering distinct advantages across administration, distribution, and patient acceptance. Over the past decade, advances in formulation science, mucosal immunology, and delivery technologies have converged to renew interest from developers and public health authorities alike. These innovations seek to reduce barriers associated with needle-based vaccination, improve thermostability to ease cold chain burdens, and exploit mucosal immune responses to interrupt pathogen transmission more effectively.

As stakeholders reassess immunization strategies, the oral vaccine proposition extends beyond convenience to encompass supply chain efficiencies and potential cost reductions in administration. In clinical contexts, oral delivery can facilitate mass immunization campaigns and targeted programs where trained personnel are scarce, thereby supporting equity goals. Concurrently, the scientific community continues to refine antigen presentation, adjuvant selection, and vector design to enhance immunogenicity across demographic groups, including pediatric and geriatric populations.

This introduction sets the stage for a nuanced examination of the drivers, barriers, and strategic considerations shaping oral vaccine development and commercialization. It emphasizes the interplay between scientific innovation, regulatory pathways, and distribution models, which collectively determine the pace at which oral vaccines transition from promising candidates to routine components of global immunization programs. The aim is to provide a balanced baseline that informs subsequent sections focused on landscape shifts, trade implications, segmentation dynamics, regional variations, corporate strategies, and pragmatic recommendations for leaders across the ecosystem.

Analysis of the transformative scientific, regulatory, distributional, and patient-driven shifts redefining the oral vaccine development and delivery paradigm

The vaccine landscape is undergoing transformative shifts driven by technological breakthroughs, altered stakeholder expectations, and evolving regulatory frameworks. At the scientific level, progress in mRNA platforms, vector design, and antigen stabilization is enabling new approaches to oral delivery that were previously impractical. These advances are complemented by improvements in formulation science that protect labile molecules from gastrointestinal degradation and target mucosal immune induction. As a result, development priorities are increasingly centered on durable mucosal immunity, dose-sparing strategies, and simplified administration.

Concurrently, public health priorities have shifted toward resilient immunization systems that can respond to both endemic pathogens and emergent threats. This focus on resilience favors modalities that simplify logistics, such as needle-free administration and formulations with relaxed cold chain requirements. Regulatory agencies are evolving their guidance to accommodate novel delivery technologies, creating clearer pathways for bridging trials and real-world evidence generation. Private sector investors and strategic partners are responding by rebalancing portfolios to include early-stage oral candidates and platform technologies that promise scalability.

Moreover, end-user expectations and healthcare delivery models are reshaping commercial approaches. Patients and caregivers increasingly prioritize convenience and minimal invasiveness, which supports the adoption of oral vaccines in community and outpatient settings. Digital health tools and telemedicine are also influencing vaccine delivery by enabling scheduling, adherence tracking, and remote monitoring. Taken together, these shifts create a dynamic playing field where scientific feasibility, regulatory clarity, patient-centered design, and distribution innovation intersect to accelerate the translation of oral vaccine concepts into practice.

Evaluation of how United States tariff measures enacted in 2025 have reshaped supply chain strategies, procurement dynamics, and manufacturing localization considerations

The cumulative impact of tariff policy changes enacted in the United States in 2025 has introduced a new set of considerations for vaccine developers, manufacturers, and procurement entities. These trade measures, while aimed at broader industrial strategy objectives, affect multiple nodes of the vaccine value chain, including the sourcing of active pharmaceutical ingredients, excipients, specialized packaging materials, and equipment used in fill-and-finish operations. As a consequence, organizations with globally distributed supply chains must reassess sourcing strategies and cost structures to mitigate exposure to increased import duties and procedural delays at ports.

In practical terms, the policy shift has accelerated conversations around supply chain localization, dual sourcing, and strategic stockpiling of critical inputs. Manufacturers are investigating nearshoring options and expanding relationships with domestic contract development and manufacturing organizations to reduce tariff-related vulnerabilities. These changes also influence contract negotiation dynamics with suppliers, where greater emphasis is placed on price transparency, freight optimization, and shared risk agreements. Procurement teams are increasingly modeling the downstream operational implications of tariffs, such as altered lead times and inventory turnover, to preserve continuity of supply for clinical programs and immunization campaigns.

For public purchasers and financing institutions, tariffs introduce complexities in budgeting and procurement timelines, prompting renewed interest in long-term supply agreements and incentivized manufacturing investments within tariff-favored jurisdictions. Importantly, the policy environment has encouraged cross-sector collaboration to balance national strategic goals with global health imperatives, including multilateral dialogues to ensure that tariff measures do not impede access to life-saving vaccines. Looking ahead, the industry is adapting through a combination of operational resilience measures, strategic partnerships, and targeted capital investments aimed at maintaining programmatic continuity while aligning with evolving trade realities.

Key segmentation insights integrating vaccine platform types, disease targets, demographic needs, and distribution channels to inform development and commercialization choices

Understanding the market requires a structured view across product, clinical, demographic, and distribution dimensions, each of which shapes development priorities and commercial approaches. Based on Vaccine Type, market analyses consider Conjugate Vaccines, Inactivated Vaccines, Live Attenuated Vaccines, mRNA Vaccines, and Subunit Vaccines, recognizing that each platform presents distinct formulation challenges and immunological profiles for oral delivery. These differences influence decisions around antigen stability, dosing schedules, and the selection of protective excipients or delivery vehicles.

Based on Disease Indication, attention is given to key targets such as Influenza, Norovirus, Poliovirus, and Rotavirus, where oral delivery can offer strategic benefits in terms of mucosal immunity and population-level transmission interruption. The landscape for each indication varies by historical precedent, clinical endpoints, and regulatory expectations, affecting the pace and complexity of development programs. Based on Age Group, distinctions among Adult, Geriatric, and Pediatric populations underscore the need to tailor formulations, dosing strategies, and safety monitoring to physiological and immunological differences across the lifespan.

Finally, Based on Distribution Channel, routes to market such as Hospitals & Clinics, Online Pharmacy, and Pharmacies define the operational requirements for packaging, labeling, and cold chain management, as well as the patient engagement and adherence supports needed. Integrating these segmentation lenses reveals nuanced commercial pathways: certain vaccine types may align more naturally with mass campaign models and hospital-based distribution, while others could be optimized for retail pharmacy or direct-to-consumer channels. This layered segmentation informs prioritization for developers and commercial teams as they balance scientific feasibility with route-to-market realities.

Regional insights highlighting how Americas, Europe Middle East & Africa, and Asia-Pacific variations drive differentiated regulatory, manufacturing, and distribution strategies

Regional dynamics exert a profound influence on vaccine development priorities, regulatory interactions, and distribution models, necessitating a differentiated approach across global markets. In the Americas, public-private partnerships, advanced clinical trial infrastructure, and a mature commercial ecosystem often accelerate pathway clarity for novel delivery technologies, while regional manufacturing capacity and procurement frameworks shape decisions around localization and strategic alliances. Market adoption is also influenced by payer structures and programmatic priorities that vary between national immunization programs and private sector channels.

Europe, Middle East & Africa present a spectrum of regulatory environments and healthcare delivery models that require adaptive strategies. In some European markets, harmonized regulatory processes and strong pharmacovigilance systems facilitate lifecycle planning, whereas in certain Middle Eastern and African contexts, emphasis is placed on affordability, cold chain logistics, and integration with existing immunization schedules. Collaborative initiatives and donor-supported procurement remain critical levers to expand access in regions where infrastructure limitations challenge distribution of temperature-sensitive products.

Asia-Pacific demonstrates substantial heterogeneity, with advanced manufacturing hubs, strong biopharmaceutical innovation ecosystems, and high-capacity public health programs in some markets, juxtaposed with emerging markets where infrastructure investments are ongoing. Regional supply chains, translational science collaborations, and differences in disease burden inform clinical trial design and deployment strategies. These regional insights underscore the need for tailored regulatory engagement, manufacturing footprint decisions, and distribution partnerships that align with local priorities and operational realities.

Strategic company-level insights on how incumbent manufacturers, biotech innovators, CDMOs, and allied technology firms are shaping competitive trajectories in oral vaccines

Competitive dynamics in the oral vaccine domain reflect a mix of established vaccine manufacturers, specialized biotech innovators, contract development and manufacturing organizations, and formulation technology providers. Established manufacturers bring experience in scale-up, regulatory navigation, and large-scale distribution, positioning them to accelerate late-stage candidates toward broad deployment when technical challenges are resolved. Biotechnology firms and academic spinouts contribute disruptive platform technologies and early-stage science, particularly in areas such as mucosal immunology, oral mRNA delivery, and protective excipient systems.

Contract development and manufacturing organizations play an increasingly central role by offering technical expertise in specialized formulation, encapsulation, and fill-and-finish processes that are critical for oral product viability. Collaboration between platform owners and CDMOs often determines speed to clinic and commercial scalability. Additionally, companies focused on cold chain optimization, packaging innovation, and digital supply chain solutions are creating complementary capabilities that reduce logistical friction and improve adherence monitoring.

Strategic partnerships, licensing arrangements, and public-private collaborations are recurring motifs, enabling risk-sharing and leveraging of complementary strengths. Intellectual property strategies and platform modularity influence competitive differentiation, as does the ability to generate robust safety and immunogenicity data across diverse populations. For stakeholders evaluating partnership prospects or competitive positioning, the emphasis is on technological fit, regulatory experience, manufacturing scalability, and the capacity to address end-to-end delivery challenges.

Actionable recommendations for leaders to accelerate oral vaccine development through technology investment, regulatory engagement, supply chain diversification, and targeted commercialization

Industry leaders should adopt a proactive, multi-dimensional strategy to translate scientific promise into accessible oral vaccine solutions while managing commercial and geopolitical risks. First, invest in platform capabilities that address formulation stability and mucosal immunogenicity, including partnerships with formulation specialists and academic centers to accelerate preclinical learnings and de-risk clinical translation. Simultaneously, integrate regulatory strategy early by engaging with agencies to clarify evidence requirements for novel delivery routes, thereby shortening development timelines and reducing uncertainty.

Operationally, diversify supply chains to mitigate exposure to trade policy shifts and material bottlenecks. Establish strategic relationships with regional manufacturing partners and CDMOs to enable flexible production footprints and responsive scaling. On the commercial side, develop distribution models that align with target demographics and channels-hospitals and clinics for high-acuity programs, pharmacies for routine adult immunizations, and online pharmacy solutions to enhance access and adherence in digitally enabled markets. Complement these efforts with digital tools for patient education, scheduling, and post-market surveillance.

Finally, prioritize stakeholder engagement to build confidence among payers, public health authorities, and community leaders. Invest in robust real-world evidence generation and pharmacovigilance frameworks to demonstrate safety and effectiveness across age groups. By balancing scientific rigor, regulatory foresight, operational resilience, and targeted commercial execution, industry leaders can position their portfolios to capture the full potential of oral vaccine innovations.

Transparent research methodology combining expert primary interviews, literature synthesis, case study analysis, and data triangulation to ensure balanced and actionable insights

This research synthesis is underpinned by a rigorous methodology that integrates primary and secondary inputs to ensure robust, defensible conclusions. Primary research included structured interviews and consultations with subject-matter experts from vaccine development, clinical research, regulatory affairs, manufacturing operations, and public health procurement, providing practical insights into technical challenges and strategic priorities. These engagements were complemented by analysis of relevant peer-reviewed literature, clinical trial registries, regulatory guidance, and technical white papers to ground findings in contemporary science and policy.

Data synthesis employed cross-validation techniques to reconcile differing perspectives and triangulate conclusions, placing particular emphasis on reproducibility of clinical and operational observations. The study also reviewed anonymized case examples of process development and distribution implementations to extract transferable lessons and risk mitigation strategies. Quality assurance steps included expert review cycles, methodological transparency for key assumptions, and iterative refinement based on stakeholder feedback to enhance applicability across diverse organizational contexts.

Where appropriate, the methodology identified areas of uncertainty and recommended targeted research to address gaps, such as comparative immunogenicity studies across delivery platforms and operational pilots for alternative distribution channels. The approach balances depth and pragmatism to deliver insights that are both scientifically grounded and operationally actionable for decision-makers.

Conclusive synthesis emphasizing the promise of oral vaccines, residual scientific and operational challenges, and the need for coordinated industry and policy action

In conclusion, oral vaccines represent a strategic opportunity to broaden the toolkit for disease prevention by offering needle-free administration, potential improvements in mucosal immunity, and distribution efficiencies that align with contemporary public health priorities. Scientific and technological advances are progressively addressing historical barriers related to antigen stability and gastrointestinal delivery, while regulatory pathways are becoming more navigable through proactive engagement. Yet, challenges remain, including the need for robust safety and efficacy data across age cohorts, scalable manufacturing processes, and adaptive distribution models that handle variable infrastructure capacities.

External factors such as trade policy shifts and regional heterogeneity in healthcare delivery further complicate the pathway to broad adoption, underscoring the importance of resilient supply chain design and region-specific strategies. Industry players that combine platform innovation, strategic partnerships, and operational agility will be best positioned to translate oral vaccine potential into sustainable public health impact. Ultimately, success will require coordinated effort among developers, regulators, manufacturers, payers, and public health stakeholders to ensure that promising technologies are translated into accessible, safe, and effective interventions that meet the needs of diverse populations.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oral Vaccine Market, by Vaccine Type

  • 8.1. Conjugate Vaccines
  • 8.2. Inactivated Vaccines
  • 8.3. Live Attenuated Vaccines
  • 8.4. Mrna Vaccines
  • 8.5. Subunit Vaccines

9. Oral Vaccine Market, by Disease Indication

  • 9.1. Influenza
  • 9.2. Norovirus
  • 9.3. Poliovirus
  • 9.4. Rotavirus

10. Oral Vaccine Market, by Age Group

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric

11. Oral Vaccine Market, by Distribution Channel

  • 11.1. Hospitals & Clinics
  • 11.2. Online Pharmacy
  • 11.3. Pharmacies

12. Oral Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Oral Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Oral Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Oral Vaccine Market

16. China Oral Vaccine Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AstraZeneca plc
  • 17.6. Bharat Biotech International Limited
  • 17.7. Emergent BioSolutions Inc.
  • 17.8. GlaxoSmithKline plc
  • 17.9. Merck & Co., Inc.
  • 17.10. Moderna, Inc
  • 17.11. Panacea Biotec Ltd.
  • 17.12. PT Bio Farma (Persero)
  • 17.13. Sanofi S.A.
  • 17.14. Sinovac Biotech Ltd
  • 17.15. Valneva SE

LIST OF FIGURES

  • FIGURE 1. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ORAL VACCINE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ORAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ORAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ORAL VACCINE MARKET SIZE, BY INACTIVATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ORAL VACCINE MARKET SIZE, BY LIVE ATTENUATED VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ORAL VACCINE MARKET SIZE, BY MRNA VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ORAL VACCINE MARKET SIZE, BY SUBUNIT VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ORAL VACCINE MARKET SIZE, BY INFLUENZA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ORAL VACCINE MARKET SIZE, BY NOROVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ORAL VACCINE MARKET SIZE, BY POLIOVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ORAL VACCINE MARKET SIZE, BY ROTAVIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ORAL VACCINE MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ORAL VACCINE MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ORAL VACCINE MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ORAL VACCINE MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ORAL VACCINE MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ORAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ORAL VACCINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS ORAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. AMERICAS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL ORAL VACCINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. GCC ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GCC ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. GCC ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. GCC ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GCC ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. BRICS ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. BRICS ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. BRICS ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. G7 ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. G7 ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. G7 ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. G7 ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. G7 ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 118. NATO ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. NATO ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. NATO ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 121. NATO ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. NATO ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL ORAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. UNITED STATES ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 125. UNITED STATES ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 127. UNITED STATES ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. UNITED STATES ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 129. CHINA ORAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 130. CHINA ORAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. CHINA ORAL VACCINE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. CHINA ORAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. CHINA ORAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)